The global COVID-19 detection kits market is estimated to be valued at US$ 4.4 Billion in 2023 and is expected to exhibit a CAGR of 2.4% during the forecast period (2023-2030).
Report Coverage |
Report Details |
Base Year: |
2022 |
Market Size in 2023: |
US$ 4.4 Bn |
Historical Data for: |
2018 to 2021 |
Forecast Period: |
2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: |
2.40% |
2030 Value Projection: |
US$ 5.2 Bn |
Global COVID-19 Detection Kits Market Share (%), By Product Type, 2023
The COVID-19 Rapid Antigen Self Test is an in vitro diagnostic test intended for qualitative detection of SARS-CoV-2 antigen from human nasal samples. This test is designed to provide rapid results, typically within 15-30 minutes, making it a convenient option for individuals who want to quickly determine their COVID-19 status. It is important to note that this test should not be used as the sole basis for diagnosis and should be confirmed with a laboratory-based PCR test if any doubts or symptoms persist. The self-test is user-friendly and does not require any specialized equipment or training to perform. It utilizes lateral flow immunoassay technology to detect the presence of SARS-CoV-2 antigen in nasal samples. However, it is crucial to follow the instructions carefully and consult with a healthcare professional for proper interpretation of the results. It is important to note that self-tests may have a higher chance of false negatives compared to laboratory-based PCR tests. Therefore, if there are concerns or persistent symptoms, it is recommended to seek further testing from a healthcare professional. Additionally, self-tests should not replace other preventive measures such as wearing masks, practicing social distancing, and following local health guidelines.
Market Dynamics
The key players in the pharmaceutical industry are focusing on the development of a new antigen rapid testing kit for the confirmation of COVID-19. Thus, the introduction of such advanced products in the market is expected to drive growth of the global COVID-19 detection kits market over the forecast period. For instance, in June 2020, JOYSBIO Biotechnology, an Research & Development-focused Chinese biotechnology company, released a new COVID-19 Antigen Rapid Test Kit (Colloidal Gold). The new coronavirus antigen test kit is a lateral flow immunoassay for the qualitative detection of SARS-COV-2 antigen (nucleocapsid protein) in upper respiratory samples with nasal swabs or saliva during the acute phase of infection.
Key features of the study:
- This report provides an in-depth analysis of the global COVID-19 detection kits market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global COVID-19 detection kits market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Co-Diagnostics, Inc., F. Hoffmann-La Roche AG, Siemens Healthineers AG, Thermo Fisher Scientific, Abbott Laboratories, BGI, Cepheid Inc., BioFire Diagnostics, GenMark Diagnostics, Qiagen, Quidel Corporation, Randox Laboratories Ltd., SD Biosensor, INC., Shenzhen Bioeasy Biotechnology Co., Ltd., Seegene Inc., JOYSBIO Biotechnology, Cipla Limited, Bione, Virax Biolabs Group Limited, SD BioSensor, Inc., NanoSpot.ai, J. Mitra & Co. Pvt. Ltd., Genes2Me, Ubio Biotechnology Systems Pvt Ltd, Bharat Biotech, Gennova Biopharmaceuticals, QRX Pharma, Angstrom Biotech Pvt. Ltd., and Detect, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global COVID-19 detection kits market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global COVID-19 detection kits market.
Detailed Segmentation:
- Global COVID-19 Detection Kits Market, By Product Type:
- RT-PCR Assay Kits
- Immunoassay Test Strips/Cassettes
- Global COVID-19 Detection Kits Market, By Specimen Type:
- Nasopharyngeal swab
- Oropharyngeal swab
- Nasal swab
- Sputum
- Others
- Global COVID-19 Detection Kits Market, By End User:
- Hospitals
- Diagnostic centers
- Others
- Global COVID-19 Detection Kits Market, By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
- Company Profiles
- Co-Diagnostics, Inc.
- F. Hoffmann-La Roche AG
- Siemens Healthineers AG
- Thermo Fisher Scientific
- Abbott Laboratories
- BGI
- Cepheid Inc.
- BioFire Diagnostics
- GenMark Diagnostics
- Qiagen
- Quidel Corporation
- Randox Laboratories Ltd.
- SD Biosensor, INC.
- Shenzhen Bioeasy Biotechnology Co., Ltd.
- Seegene Inc.
- JOYSBIO Biotechnology
- Cipla Limited
- Bione
- Virax Biolabs Group Limited
- SD BioSensor, Inc.
- ai
- Mitra & Co. Pvt. Ltd.
- Genes2Me
- Ubio Biotechnology Systems Pvt Ltd
- Bharat Biotech
- Gennova Biopharmaceuticals
- QRX Pharma
- Angstrom Biotech Pvt. Ltd.
- Detect, Inc.